Editas Medicine Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (49)

View All

Latest Posts

About This Stock More About This Stock
What Is CRISPR And Why Should Your Portfolio Care?
Article By: Fred Fuld III
Sunday, June 25, 2023 3:01 PM EDT
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.
In this article: NVS, EDIT, NTLA, CRSP
Read
Top CRISPR Stocks
Article By: Fred Fuld III
Saturday, February 11, 2023 9:09 PM EDT
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
In this article: EDIT, NTLA, CRSP Also: NVS
Read
The Best Dressed Chart Patterns Of 2020 - Part I
Article By: Macro-Ops
Sunday, January 3, 2021 2:24 AM EDT
Our goal for the year was simple: Identify and trade the best-looking classical chart set-ups. We've broken it into sections by chart pattern and the best set-ups in those patterns.
In this article: LGND, AEO, NLS, NYT, WLK, DMTK, LB, AMRK, ICBK, EDIT, CINR, AIH, HPR, TBIIF, CELH, PTON Also: VOLVF
Read
Top ETF Of December & Its Best Stocks
Article By: Sweta Killa
Thursday, December 24, 2020 4:58 PM EDT
Although most of the stocks in the ARKG fund’s portfolio delivered strong returns, a few gained at least 80% last month. Here are the five best-performing stocks in the ETF with their respective positions in the basket.
In this article: BEAM, PACB, EDIT, SYRS, AQB Also: ARKG
Read
Editas Medicine: CRISPR Gene Editing Leader
Article By: GreenDotStocks
Wednesday, November 11, 2020 9:35 AM EDT
Editas is focused on the CRISPR gene-editing technology, which promises solutions to hereditary and chronic diseases. An exciting story, but is it investable?
In this article: EDIT
Read
All Posts

Latest Tweets for $EDIT

No tweets yet!

PARTNER HEADLINES

$EDIT

Comments Status Updates
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Michael Molman • 12/6/2017 5:41:11 PM

Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.

1 to 1 of 1 comments